Taxol Boosts Odds of Chronic Pain

Breast cancer patients getting the chemo drug may suffer long-term neuropathic discomfort, study finds

Related Encyclopedia • Adenocarcinoma of the Lung and Brain Metastases • Amenorrhea • Amniocentesis • Amniocentesis and CVS More... Related Healthscout Videos Growing Lungs in the Lab: Medicine's Next Big Thing? First Spinal Fusion Reversal in the U.S. From Belly to Breast: Rebuilding After Cancer Laser Surgery Saves Twins More... Related Animations • Breast Reduction • Breast Self-Exam Video • Colon Cancer • Erectile Dysfunction More... Related Drug Information • Actonel • Detrol LA • Diflucan • Ditropan XL More... Related News Articles • Long-Term Statin Use Won't Up Cancer Risk: Study • Smokers Urged to Join Thursday's Great American Smokeout • Spleen Cells Tied to Damage of Spinal Cord Injury in Animal Study • FDA Advisers Renew Review on Whether to Ban Menthol Cigarettes More...

MONDAY, Nov. 30 (HealthDay News) -- The chemotherapy drug paclitaxel (Taxol) increases the risk of chronic neuropathic pain in breast cancer survivors, a new study shows.

It included 240 women who took part in clinical trials of Taxol between 1994 and 2001. Those who experienced chemotherapy-induced peripheral neuropathy during their treatment with Taxol were three times more likely to eventually be diagnosed with chronic neuropathic pain.

Text Continues Below

---

The study is published in the November issue of the Journal of Pain.

The findings indicate that patients treated with Taxol should be regularly monitored for neuropathic pain after their chemotherapy ends, said the researchers from the University of Texas M.D. Anderson Cancer Center.

In certain cases, patients and doctors should review the risks and benefits for continuing treatment with Taxol if a patient is likely to experience worsening neuropathy, the study authors added.

They noted that the same cellular mechanism that's altered by Taxol to kill tumors can be toxic to normal tissue.

More information

The National Pain Foundation has more about neuropathic pain.

-- Robert Preidt